$18.030
-0.719 (-3.99%)收盤時
JANX 資訊
JANX 事件
Janux Reports Q2 Revenue of $10.267M, Below Consensus
Reports Q2 revenue $10.267M, consensus $17.94M. "During the second quarter we continued to execute across our clinical portfolio while preparing for multiple upcoming milestones," said David Campbell, Ph.D., President and Chief Executive Officer of Janux. "Enrollment continues across our prostate cancer programs, including JANX007 and JANX014, and we remain on track to initiate clinical development of JANX013 later this year. We also continue to make progress with JANX011 in healthy volunteers as we advance our autoimmune disease pipeline."
Tech Stocks Plummet Due to Valuation Concerns
Valuation concerns in the AI capex buildout economy hit the Tech sector - by far the worst performing area of the S&P 500 - particularly hard on Tuesday. 2026 memory and semiconductor highflyers were some of the biggest lowers, as Micronand Sandiskwere the worst performers on the benchmark. Among the positive areas, the resilient labor market and questions about AI displacement in the human economy have supported Staffing/Employment, as companies like Korn Ferryrallied by over 6% after better than feared results. Otherwise, the unwind in Tech momentum trade saw sector rotation into the defensive sectors, with Consumer Staples and Healthcare outperforming.In the opening hours of the evening session, equity futures are marginally higher - S&P e-minis are up a decimal and Nasdaq 100 contract is up 0.2%. In commodities, the perception of progress in the Strait of Hormuz has pressured WTI Crude Oil to low $70s. Meanwhile the accelerating strength in the U.S. Dollar is weighing deeper on all metals - Gold is below $4,120 and Silver has retreated below $62 per ounce while Copper is at the lowest level since mid-May below $6.15/lb.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Icon plcup 5.1%KB Homeup 3.8%ALSO HIGHER -National Health Investorsup 4.0% after entering S&P SmallCap 600 indexToastup 3.7% after entering S&P MidCap 400 indexIES Holdingsup 3.2% after entering S&P MidCap 400 indexNikeup 1.0% after naming new CFO and affirming guidanceHoneywell Internationalup 0.9% after entering S&P 500 indexAlphabetup 0.7% after entering Dow Jones Industrials AverageDOWN AFTER EARNINGS -Worthingtondown 9.9%Cerebras Systemsdown 10.7%FedExdown 6.3%ALSO LOWER -Janux Therapeuticsdown 3.4% after departure of Chief Medical Officer
Janux Reports Q1 Revenue of $3.7M
Reports Q1 revenue $3.7M, consensus $4.7M. "Our commitment to advancing a prostate cancer franchise is demonstrated by our continued progress with JANX007, clinical initiation of JANX014, and advancement of JANX013 toward the clinic," said David Campbell, Ph.D., President and CEO of Janux. "Our ongoing clinical study with JANX011 has been designed to support our emerging autoimmune disease opportunity."
Janux Therapeutics Discontinues Clinical Development of JANX008
Janux Therapeutics announced that it will discontinue further clinical development of JANX008, its EGFR-targeted Tumor Activated T Cell Engager program. Following completion of the Phase 1a portion of the study, which included dose escalation and expansion cohorts across multiple solid tumor indications, and an internal review of the data, the Company has determined to prioritize development resources toward other pipeline opportunities. The decision to discontinue JANX008 is program-specific and does not impact the Company's broader TRACTr platform strategy. As part of its disciplined portfolio prioritization process, the Company evaluated the JANX008 dataset against predefined development criteria. While durable responses were observed in select patients through extended follow-up, the overall magnitude and consistency of activity were not sufficient to support continued development relative to other pipeline programs. The study also generated insights relevant to the broader TRACTr platform. The occurrence of cytokine release syndrome (CRS) was infrequent and primarily limited to Grade 1, enabling Safety Review Committee approval for outpatient dosing. In addition, JANX008 demonstrated a differentiated tolerability profile relative to conventional EGFR-targeted therapies, with minimal gastrointestinal, dermatologic, and subcutaneous adverse events typically associated with EGFR antibodies and tyrosine kinase inhibitors. These findings, together with the ability to dose beyond the limitations of conventional T cell engagers, support the potential of the TRACTr platform to improve safety. While musculoskeletal adverse events were dose-limiting, reflecting constraints associated with the EGFR target, the TRACTr format enabled a sufficient therapeutic window to assess clinical activity across a range of doses.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。